title: Efficacy of apraclonidine ophthalmic solution (Iopidine) in presumed silicon oil-induced glaucoma and primary open-angle glaucoma.
abstract: BACKGROUND
  This pilot study evaluated the acute effects of topical ocular apraclonidine 1% (Iopidine) in 10 patients with presumed silicone oil-induced secondary glaucoma (SOIG) and in 10 patients with high-pressure primary open-angle glaucoma (POAG) despite maximum tolerated medical therapy.
  
  
  METHODS
  Intraocular pressure (IOP) measurements were carried out before and 1, 2 and 3 h after a single drop of apraclonidine.
  
  
  RESULTS
  Patients with SIOG presented with a mean IOP of 30.0 +/- 2.8 mmHg, which was reduced to 21.7 +/- 2.9 mmHg (P < 0.001) after 1 h, to 20.4 +/- 2.3 mmHg (P < 0.001) after 2 h and to 20.0 +/- 2.5 mmHg (P < 0.001) after 3 h. In the POAG group, IOP was reduced from 25.9 +/- 1.9 mmHg before treatment to 18.9 +/- 1.4 mmHg after 1 h (P < 0.001), 17.7 +/- 1.2 mmHg after 2 h (P < 0.001) and 16.9 +/- 0.9 mmHg after 3 h (P < 0.001). There were no significant changes in blood pressure or pulse rate.
  
  
  CONCLUSIONS
  This study confirmed the activity of apraclonidine as an IOP suppressant.
authors.affiliation: University Eye Hospital, Würzburg, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Gramer
authors.forename: S
authors.initials: S
authors.lastname: Busche
authors.forename: A
authors.initials: A
authors.lastname: Kampik
authors.forename: D
authors.initials: D
authors.lastname: Parsons
mesh_terms: D000293:Adolescent; D000316:Adrenergic alpha-Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003000:Clonidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004361:Drug Tolerance; D005260:Female; D005901:Glaucoma / Q000139:chemically induced / Q000188:drug therapy*; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D010865:Pilot Projects; D012827:Silicone Oils / Q000009:adverse effects*; D016896:Treatment Outcome; D014821:Vitrectomy
chemical_list: D000316:Adrenergic alpha-Agonists; D009883:Ophthalmic Solutions; D012827:Silicone Oils; C016986:apraclonidine; D003000:Clonidine